C91.1 Chronic lymphocytic leukemia of B-cell type

Name of the Condition

• Chronic lymphocytic leukemia of B-cell type
• ICD-10 Code: C91.1

Summary

Chronic lymphocytic leukemia of B-cell type (CLL) is a slow-growing cancer of the blood and bone marrow that affects B lymphocytes, a type of white blood cell. It involves the accumulation of abnormal, mature-appearing lymphocytes in the blood, bone marrow, and lymphoid tissues. CLL is the most common adult leukemia in Western countries and typically progresses gradually, though some cases may transform into more aggressive forms.

Causes

The exact cause of CLL is not fully understood, but it involves genetic mutations in B lymphocytes that disrupt normal cell regulation. Contributing factors may include environmental exposures, genetic predispositions, and alterations in immune system function. Unlike acute leukemias, CLL is characterized by the expansion of mature but dysfunctional lymphocytes rather than immature cells.

Risk Factors

• Increasing age (most common in adults over 60)
• Family history of CLL or other lymphoid cancers
• Certain genetic conditions (e.g., inherited immune disorders)
• Prior exposure to certain chemicals or radiation (less clearly established)

Symptoms

• Fatigue and weakness
• Swollen lymph nodes (especially in the neck, armpits, or groin)
• Enlarged spleen or liver
• Frequent infections due to impaired immune function
• Unexplained weight loss
• Night sweats
• Easy bruising or bleeding (less common)

Diagnosis

Diagnosis involves a physical examination, followed by blood tests to assess lymphocyte counts and identify abnormal cell characteristics. Flow cytometry or immunophenotyping is used to confirm B-cell origin. A bone marrow biopsy may be performed to evaluate cellularity and rule out other conditions. Additional tests, such as genetic or molecular studies, may help assess prognosis.

Treatment Options

Treatment depends on disease stage, symptoms, and overall health. Early-stage CLL without symptoms may be monitored (watchful waiting). Active treatment options include targeted therapies (e.g., BTK inhibitors, BCL-2 inhibitors), immunotherapy (e.g., monoclonal antibodies), and chemotherapy. Stem cell transplantation may be considered for select patients with aggressive disease or relapse.

Prognosis and Follow-Up

Prognosis varies widely, with some patients living for years without treatment. Factors like genetic mutations and disease stage influence outcomes. Regular follow-up with blood tests and clinical assessments is standard to monitor disease progression or response to therapy. Advanced age or comorbidities may impact treatment tolerance and survival.

Complications

• Increased risk of infections due to impaired immune function
• Autoimmune disorders (e.g., hemolytic anemia, thrombocytopenia)
• Transformation to a more aggressive lymphoma (Richter's transformation)
• Bone marrow failure leading to anemia, thrombocytopenia, or neutropenia
• Enlargement of lymph nodes, spleen, or other organs causing discomfort

Lifestyle & Prevention

• Maintain a balanced diet and regular exercise to support overall health
• Practice good hygiene to reduce infection risk
• Avoid exposure to known carcinogens (e.g., tobacco, excessive radiation)
• Stay up-to-date with vaccinations (as recommended by a healthcare provider)
• Manage stress and prioritize rest to support immune function

When to Seek Professional Help

Seek medical attention if you experience persistent fatigue, unexplained weight loss, night sweats, or swollen lymph nodes. Prompt evaluation is important if you develop frequent infections, unexplained bruising, or bleeding, as these may indicate disease progression or complications.

Tips for Medical Coders

Document the diagnosis of chronic lymphocytic leukemia of B-cell type (C91.1) with specificity, including clinical findings, laboratory results, and any relevant staging or prognostic information. Ensure documentation supports the B-cell lineage, as this distinguishes it from other lymphoid leukemias. Include details about disease activity, treatment response, or complications if applicable, as these may impact coding accuracy and downstream workflows.